{"DataElement":{"publicId":"2787403","version":"3","preferredName":"Anti-Thymocyte Globulin Or Antilymphocyte Serum Source Animal Type","preferredDefinition":"A description of the animal source for anti-thymocyte globulin or antilymphocyte serum.","longName":"2787412v1.0:2488536v2.1","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2787412","version":"1","preferredName":"Anti-Thymocyte Globulin Or Antilymphocyte Serum Source","preferredDefinition":"A purified gamma immunoglobulin (IgG) with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Immunoglobulins raised xenogeneically against lymphocyte populations.  It is used both as a test for histocompatibility and in conjunction with other immunosuppressive agents to suppress rejection of grafts or organ transplants._Where something is available or from where it originates.","longName":"ATG_OR_ALS_SRC","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2861802","version":"1","preferredName":"Antithymocyte Globulin Or Antilymphocyte Serum","preferredDefinition":"A purified gamma immunoglobulin with immunosuppressive properties.  Obtained from rabbits that have been immunized with human thymocytes, antithymocyte globulin specifically recognizes and destroys T lymphocytes.  Although the exact mechanism of action is not completely understood, it appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering antithymocyte globulin with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host disease. (NCI04):Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:Immunoglobulins raised xenogeneically against lymphocyte populations.  It is used both as a test for histocompatibility and in conjunction with other immunosuppressive agents to suppress rejection of grafts or organ transplants.","longName":"C278:C37998:C62577","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-Thymocyte Globulin","conceptCode":"C278","definition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antilymphocyte Serum","conceptCode":"C62577","definition":"Immunoglobulins raised xenogeneically against lymphocyte populations.  It is used both as a test for histocompatibility and in conjunction with other immunosuppressive agents to suppress rejection of grafts or organ transplants.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6811B47C-6B53-8BA0-E040-BB89AD4309AA","latestVersionIndicator":"Yes","beginDate":"2009-04-21","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-04-21","modifiedBy":"ONEDATA","dateModified":"2009-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2223297","version":"1","preferredName":"Source","preferredDefinition":"Where something is available.","longName":"C25683","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Source","conceptCode":"C25683","definition":"Where something is available or from where it originates.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62B04C0-71B2-23A7-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"57A6D22E-9602-6172-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-04-28","endDate":null,"createdBy":"LEATHERJ","dateCreated":"2008-09-24","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2488536","version":"2.1","preferredName":"Animal Sources Type","preferredDefinition":"indicates whether horse, rabbit or some other source was used in conjunction with human lymphoid or other cells for the creation of the drug_Something distinguishable as an identifiable class based on common qualities.","longName":"2488536v2.1","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"28C0614F-7AB1-3056-E050-BB89AD4346BB","beginDate":"2016-01-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-07","modifiedBy":"ONEDATA","dateModified":"2016-01-07","deletedIndicator":"No"},{"value":"Thymoglobulin (rabbit)","valueDescription":"Rabbit Anti-Thymocyte Globulin","ValueMeaning":{"publicId":"5097251","version":"1","preferredName":"Rabbit Anti-Thymocyte Globulin","longName":"5097251","preferredDefinition":"Various members of the family Leporidae, especially those of the genus Sylvilagus.: A purified gamma immunoglobulin (IgG) with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rabbit","conceptCode":"C14264","definition":"Various members of the family Leporidae, especially those of the genus Sylvilagus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Anti-Thymocyte Globulin","conceptCode":"C278","definition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C0614F-7ABE-3056-E050-BB89AD4346BB","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"28C0614F-7AD7-3056-E050-BB89AD4346BB","beginDate":"2016-01-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-07","modifiedBy":"ONEDATA","dateModified":"2016-01-07","deletedIndicator":"No"},{"value":"ATGAM (horse)","valueDescription":"Horse Anti-Thymocyte Globulin","ValueMeaning":{"publicId":"5097253","version":"1","preferredName":"Horse Anti-Thymocyte Globulin","longName":"5097253","preferredDefinition":"The domestic horse, Equus caballus.: A purified gamma immunoglobulin (IgG) with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Horse","conceptCode":"C14222","definition":"The domestic horse, Equus caballus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Anti-Thymocyte Globulin","conceptCode":"C278","definition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C0614F-7B0A-3056-E050-BB89AD4346BB","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"28C0614F-7B23-3056-E050-BB89AD4346BB","beginDate":"2016-01-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-07","modifiedBy":"ONEDATA","dateModified":"2016-01-07","deletedIndicator":"No"},{"value":"Horse","valueDescription":"horse","ValueMeaning":{"publicId":"2580041","version":"1","preferredName":"horse","longName":"2580041","preferredDefinition":"The domestic horse, Equus caballus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Horse","conceptCode":"C14222","definition":"The domestic horse, Equus caballus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-05B6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-22","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-22","modifiedBy":"CURTIST","dateModified":"2007-03-29","changeDescription":"03/29/2007 - Updated with NCI Thesaurus definition and concept code.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"209435FB-626F-8B2A-E050-BB89AD43399C","beginDate":"2006-06-22","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"},{"value":"Rabbit","valueDescription":"Rabbit","ValueMeaning":{"publicId":"3179728","version":"1","preferredName":"Rabbit","longName":"3179728","preferredDefinition":"Various members of the family Leporidae, especially those of the genus Sylvilagus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rabbit","conceptCode":"C14264","definition":"Various members of the family Leporidae, especially those of the genus Sylvilagus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F3BAD1-2BE8-DD20-E040-BB89AD431896","latestVersionIndicator":"Yes","beginDate":"2011-01-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"209435FB-6279-8B2A-E050-BB89AD43399C","beginDate":"2013-09-06","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"},{"value":"ATG - Fresenius (rabbit)","valueDescription":"Fresenius Biotech Anti-Thymocyte Globulin","ValueMeaning":{"publicId":"5097252","version":"1","preferredName":"Fresenius Biotech Anti-Thymocyte Globulin","longName":"5097252","preferredDefinition":"A German company that researches, develops, and markets biopharmaceuticals for the treatment of severe diseases.: A purified gamma immunoglobulin (IgG) with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fresenius Biotech","conceptCode":"C124044","definition":"A German company that researches, develops, and markets biopharmaceuticals for the treatment of severe diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Anti-Thymocyte Globulin","conceptCode":"C278","definition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C0614F-7AE4-3056-E050-BB89AD4346BB","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"44A951B8-B04D-1EA7-E053-F662850ACCF8","beginDate":"2016-01-07","endDate":null,"createdBy":"NYCHM","dateCreated":"2016-12-27","modifiedBy":"ONEDATA","dateModified":"2016-12-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2182571","version":"1","preferredName":"Pharmacologic Substance","preferredDefinition":"A natural, synthetic or semi-synthetic substance including endogenous body substance used to diagnose, prevent, maintain, treat or analyze abnormal and normal biological functions in vivo or in vitro.","longName":"PHARMACOLOGIC SUBSTANCE","context":"caCORE","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"D727D9B9-FB5E-1E8C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-04-03","endDate":null,"createdBy":"DWARZEL","dateCreated":"2004-04-03","modifiedBy":"DWARZEL","dateModified":"2004-05-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2488535","version":"1","preferredName":"Animal Sources Type","preferredDefinition":"No Value Exists:Type; a subdivision of a particular kind of thing.","longName":"C18634:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Animal Sources","conceptCode":"C18634","definition":"Indicates that a product is derived from an animal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"16D1B008-533A-4B01-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-22","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-22","modifiedBy":"ONEDATA","dateModified":"2006-06-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"209435FB-6258-8B2A-E050-BB89AD43399C","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"NYCHM","dateModified":"2017-02-03","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964902","version":"1","longName":"2100r1: 100 Days Post-HSCT Data","context":"NHLBI"},{"publicId":"2964922","version":"1","longName":"2200r1: 6 Month to 2 Year Post-HSCT Data","context":"NHLBI"},{"publicId":"2964923","version":"1","longName":"2300r1: Greater Than 2 Years Post-HSCT Data","context":"NHLBI"}]},{"publicId":"2842912","version":"1","longName":"Therapy","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2842918","version":"1","longName":"Administration","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"Animal:speciesCode","type":"HCT_BRIDG","context":"NHLBI"},{"name":"PreTed_gvhd_prophy_med_animal_source_type","type":"NMDP_FN","context":"NHLBI"},{"name":"PreTed_pre_hct_med_animal_source_type","type":"NMDP_FN","context":"NHLBI"},{"name":"HPST_AGHD_med_animl_srce_type","type":"NMDP_FN","context":"NHLBI"},{"name":"HPST_AGHD_p_med_anim_srce_ty","type":"NMDP_FN","context":"NHLBI"},{"name":"HPST_CGHD_med_animl_srce_type","type":"NMDP_FN","context":"NHLBI"},{"name":"PreTed_gvhd_pr_med_ani_src_typ","type":"NMDP_FN","context":"NHLBI"},{"name":"PreTed_hct_med_animl_srce_type","type":"NMDP_FN","context":"NHLBI"},{"name":"CPRE_STPC_med_animl_srce_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Specify source","type":"Application Standard Question Text","description":"Specify source","url":null,"context":"NHLBI"},{"name":"Specify the ALS, ALG, ATS, AT","type":"Preferred Question Text","description":"Specify the ALS, ALG, ATS, ATG animal source:","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2787403","type":"BRIDG Mapping Path","description":"\"PerformedProcedure > SubstanceExtractionAdministrationRelationship > PerformedSubstanceExtraction > Subject [donor] > Animal.speciesCode WHERE PerformedProcedure > DefinedProcedure.reasonCode = \"\"Preventive Intervention of GVHD\"\" AND DefinedProcedure > DefinedCompositeRelationship > DefiendActivity AND DefinedActivity.nameCode = \"\"Perform composite preparative regimen\"\"\"","url":null,"context":"NHLBI"},{"name":"Specify source","type":"Alternate Question Text","description":"Specify source","url":null,"context":"NHLBI"},{"name":"Specify ATG","type":"Alternate Question Text","description":"Specify ATG","url":null,"context":"NHLBI"},{"name":"Specify ALG, ALS, ATG, ATS source","type":"Alternate Question Text","description":"Specify ALG, ALS, ATG, ATS source","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"209435FB-6294-8B2A-E050-BB89AD43399C","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"MALUMK","dateModified":"2021-03-24","changeDescription":".AQT added for 2100r7. 03/24/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}